ESTIMATION OF EFFICIENCY AND SAFETY OF APPLICATION AQUA MARIS® ECTOIN (ANS01) NASAL SPRAY IN THE THERAPY OF ALLERGIC RHINITIS IN PREGNANT WOMEN

2019 ◽  
Vol 25 (3) ◽  
pp. 94-103
Author(s):  
M.A. Ryabova ◽  
◽  
L.V. Georgieva ◽  
Keyword(s):  
Allergic Rhinitis ◽  
Pregnant Women ◽  
Nasal Spray ◽  
Nasal Mucosa ◽  
Clinical Symptoms ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Reproductive Age ◽  
Childbearing Age ◽  
Open Label

The prevalence of allergic diseases is increasing: according to recent data, about 20% of the worlds' population suffers from allergic rhinitis. About 30% of the reproductive age women are known to suffer from allergic rhinitis, and in a third of cases, symptoms of allergic rhinitis increase during pregnancy. Allergic inflammation is the result of contact with a causative allergen and elimination of causative allergens is not always possible. The creation of a protective barrier preventing the adhesion of allergens on the surface of the nasal mucosa reduces the penetration of allergens and helps control allergic rhinitis. Aqua Maris® Nasal Spray Ectoin is a completely natural remedy that creates a physical barrier (“barrier”) for attaching allergens to the nasal mucosa and prevents the development of allergic rhinitis. Aqua Maris® Ectoin can be used for allergic rhinitis treatment in pregnant and nursing women. Non-comparative open-label trial investigating the efficacy and safety of the Aqua Maris® Nasal Spray Ectoin was carried out from September to June 2019 at the Center of early diagnosis of allergic diseases in women of childbearing age Pavlov First Saint Petersburg State Medical University. The study included 45 pregnant women with allergic rhinitis. Clinical efficacy was evaluated by the severity of clinical symptoms and rhinoscopic data of patients in dynamics during treatment. As a result of the use of Aqua-Maris Ectoin in pregnant women, a significant reduction in complaints on the 10th day of therapy and a decrease in inflammatory phenomena in the nasal cavity were observed. In addition, a significantly significant decrease in secretory nasal IgE was noted. This indicates the effectiveness of the Aqua Maris® Nasal Spray Ectoin in the treatment of allergic rhinitis in pregnant women. Adverse events associated with the use of Ectoin Aqua Maris® Nasal Spray in pregnant women were not detected. Aqua Maris® Nasal Spray Ectoin can be used for effective and safe treatment of allergic rhinitis in pregnant women.

scholarly journals CLINICAL EFFICIENCY AND ANTI-INFLAMMATORY ACTIVITYOF THERAPY IN CHILDREN WITH PERENNIAL ALLERGICRHINITIS

2010 ◽  
Vol 7 (6) ◽  
pp. 52-59
Author(s):  
V I Petrov ◽  
N V Maljuzhinskaya ◽  
I N Shishimorov ◽  
A V Razvalyaeva
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Treatment Guidelines ◽  
Clinical Symptoms ◽  
Combined Therapy ◽  
Bronchial Hyperresponsiveness ◽  
Allergic Inflammation ◽  
Open Label ◽  
Old Patients ◽  
Intranasal Corticosteroids

Background. Intranasal corticosteroids and nonsedating antihistamines are the drug classes most often prescribed to treat allergic rhinitis (AR). Treatment guidelines recommend a combination of these agents for moderate to severe AR. Objective: To compare the efficacy of mometasone furoate (MF) nasal spray plus desloratadine (DL) with that of monotherapy with the individual agents in 6-16 years old patients with perennial AR. Methods. A prospective, randomized, open label, parallel group study of the efficiency of MF nasal spray plus DL and of monotherapy with MF or DL in children with persistent allergic rhinitis aged 6-16 in a 12week period was conducted. The efficacy of therapy was evaluated by level of markers of an allergic inflammation, indicators of a bronchial hyperresponsiveness and by dynamics of clinical symptoms. Results. Combined therapy (DL+MF) restores balance of cytokines: increase the Тh1 activity and decrease the Т2 activity. Combined therapy found to be effective in the majority of AR patients. Сnclusion. Combined therapy with MF and DL in the treatment of perennial AR in children has clinical advan60

scholarly journals Difficult nasal breathing in the ENT-practice: how to help?

2020 ◽  
Vol 19 (2) ◽  
pp. 107-115
Author(s):  
S. V. Ryazantsev ◽  
◽  
S. S. Pavlova ◽  
Keyword(s):  
Nasal Cavity ◽  
Nasal Obstruction ◽  
Nasal Spray ◽  
Clinical Symptoms ◽  
Nasal Congestion ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Vascular Wall ◽  
Medical Documentation ◽  
Nasal Breathing

The article discusses the most common causes of diseases that cause difficulty in nasal breathing. According to the analysis of medical documentation, diseases accompanied by nasal obstruction and rhinorrhea are the most common human diseases. The priority role in the development of the clinical symptoms of rhinitis is played by the release of inflammatory mediators – histamine and bradykinin. Histamine in rhinitis mediates a cascade of pathological reactions, as a result of which local vasodilation develops, accompanied by swelling of the mucous membranes; nasal congestion; increased permeability of the vascular wall; exudation of blood plasma; irritation of nerve endings; triggering reflex mechanisms by stimulating trigeminal histamine receptors. Peculiarities of the course of intermittent and persistent forms of allergic rhinitis, the pathogenesis of allergic inflammation are considered. To reliably eliminate abundant rhinorrhea, combined with nasal congestion, the authors recommend the use of a combined nasal spray, which contains phenylephrine and cetirizine (Phenylephrine + Cetirizine). Based on the analysis of literature data, the effectiveness and safety of the use of the topical form of cetirizine are substantiated. Aspects of the clinical use of the combination of phenylephrine and cetirizine in inflammatory and allergic diseases of the nasal cavity and paranasal sinuses, in the pathogenesis of which the key role is played by swelling of the mucous membrane of the nasal cavity, are examined. It is proved that the new combined nasal spray of domestic production is an effective and safe method for treating patients with manifestations of various forms of rhinitis and nasal obstruction.

scholarly journals A comparative study to assess the efficacy of fluticasone and mometasone in allergic rhinitis

2020 ◽  
Vol 6 (9) ◽  
pp. 1587
Author(s):  
Waqar Ul Hamid ◽  
Deepshikha Sumbria ◽  
Ihsan Ali ◽  
Rauf Ahmad
Keyword(s):  
Allergic Rhinitis ◽  
Comparative Study ◽  
Nasal Spray ◽  
Allergic Diseases ◽  
Therapeutic Benefit ◽  
Nasal Symptom ◽  
Open Label ◽  
Nasal Sprays ◽  
Parallel Group ◽  
The Difference

<p class="abstract"><strong>Background:</strong> Allergic rhinitis is the most prevalent of allergic diseases in the world. Pharmacotherapy remains the mainstay of treatment.  Nasal corticosteroids being the most applicable drugs for its treatment. The objective of this study was to compare the efficacy of fluticasone propionate (FP) and mometasone furoate (MF) nasal sprays in the treatment of allergic rhinitis based on total nasal symptom score (TNSS) questionnaire.</p><p class="abstract"><strong>Methods:</strong> A prospective, randomized, open-label, parallel-group, comparative study was conducted among 80 allergic rhinitis patients fulfilling the inclusion and exclusion criteria. They were randomly assigned to two groups: FP and MF groups. FP group received 200 µg dose of FP nasal spray (1 spray/nostril) daily and the MF group received 100 µg dose of MF nasal spray (1 spray/nostril) daily for 8 weeks. The effects of the two agents were compared based on TNSS questionnaire in 0, 4 and 8 weeks after the beginning of the treatment.  </p><p class="abstract"><strong>Results:</strong> At the end of eight weeks of treatment, both groups showed statistically significant (p&lt;0.005) improvements from their baseline TNSS. Mean TNSS was reduced from to 9.46 to 2.716 in FP group and from 10.18 to 2.504 in MF group.</p><p class="abstract"><strong>Conclusions:</strong> Both the groups showed a significant therapeutic benefit in patients with allergic rhinitis. Even though, the difference between the two is not significant for 8 weeks therapy.   </p>

scholarly journals New opportunities in the allergic rhinitis therapy

2021 ◽  
pp. 118-124
Author(s):  
K. S. Pavlova ◽  
D. S. Mdinaradze
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Fixed Combination ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Developed Countries ◽  
Rapid Onset ◽  
Mometasone Furoate ◽  
High Efficacy ◽  
Intranasal Corticosteroids

Allergic rhinitis (AR) is one of the most common allergic diseases, especially in economically developed countries, including Russia. The main goal of AR therapy is the control achievement over the disease symptoms, the minimizing of the future exacerbations risks and side effects. Antihistamines and glucocorticosteroids are the main classes of medicines used in all allergic diseases, including AR. According to the Federal Clinical Guidelines for Allergic rhinitis the use of the intranasal corticosteroids in combination with antihistamines is recommended on the second stage of therapy and higher. Both classes of medicines have a complementary effect on the allergic inflammation pathogenesis main stages. The intranasal corticosteroids and antihistamines using allows the delivery of the medicines to the allergic inflammation area directly. Modern intranasal corticosteroids have a high affinity that provides the high efficacy in the low concentrations using and the insignificant systemic bioavailability. The review presents the key characteristics of the olopatadine and mometasone furoate nasal spray in a fixed combination, which registered in the Russian Federation recently. This combination is recommend for use in adults and children over 12 y.o. with allergic rhinitis. The pharmacological characteristics of the nasal spray components including the action mechanism described. The main clinical studies results presented, that confirmed the high efficacy and safety of olopatadine/mometasone furoate combination in AR patients. The olopatadine and mometasone furoate fixed combination ensures the rapid onset and the long-lasting effect with minimal adverse events risks that increases compliance and leads to the control achievement over the AR symptoms.

ОЦЕНКА ЦИТОКИНОВОГО ПРОФИЛЯ СЫВОРОТКИ КРОВИ И СУБПОПУЛЯЦИЙ Т-ЛИМФОЦИТОВ У ДЕТЕЙ С АЛЛЕРГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ОРГАНОВ ДЫХАНИЯ

2019 ◽  
pp. 52-60
Author(s):  
E.V. Prosekova ◽  
A.I. Turyanskaya ◽  
N.G. Plekhova ◽  
M.S. Dolgopolov ◽  
V.A. Sabynych
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Control Group ◽  
Healthy Children ◽  
Serum Cytokine ◽  
Immunological Parameters ◽  
Low Level ◽  
Level Of Significance

Расширение спектра изучаемых клонов Тхелперов определило более сложные иммунные механизмы реализации аллергического воспаления. Цель. Характеристика показателей и взаимосвязей цитокинового профиля сыворотки и субпопуляционного состава Тлимфоцитов периферической крови у детей с бронхиальной астмой и аллергическим ринитом. Материалы и методы. Проведено комплексное обследование 150 детей в возрасте 311 лет с верифицированным диагнозом бронхиальной астмы, аллергического ринита и 30 здоровых сверстников. Иммунологические параметры крови оценивали методом проточной цитометрии, концентрации интерлейкинов и IgE в сыворотке крови определяли методом твердофазного иммуноферментного анализа. При статистической обработке использовали программы Statistica 10 с критическим уровнем значимости р0,05. Результаты. У детей с аллергическими заболеваниями в сыворотке крови определены высокие уровни содержания интерлейкинов4, 8, 13, 17А, сопоставимый с показателями группы контроля уровень IL17F и низкое содержание IFNy. При бронхиальной астме и аллергическом рините у детей выявлено увеличение количества CD3CD8CD45RO, CD3CD8CD45RACD45RO Тлимфоцитов и CD3CD4 Тхелперов и повышение количество Th17 при снижении CD3CD4CD45RO клеток памяти. В группе здоровых детей популяция Th17 составляла 9,491,6, у детей с аллергическими заболеваниями количество данных клеток было значимо выше 14,50,77 (р0,001). Анализ сывороточного содержания цитокинов у детей с изолированным течением БА и в сочетании с аллергическим ринитом выявил разнонаправленные корреляции, отличающиеся по силе и направленности от таковых в группе здоровых детей. Заключение. У детей при изолированном течении бронхиальной астмы и в сочетании с аллергическим ринитом выявлены: сопоставимое с показателями здоровых детей количество CD3CD4 Тклеток, дисбаланс в субпопуляционном составе Тхелперов за счет преобладания Th2 и Th17, активация синтеза IL17A, IL4, IL8, IL13, низкий уровень сывороточного IFNy, изменения силы и направленности взаимосвязей цитокинового профиля и спектра субпопуляций Тлимфоцитов.Expansion of the range of examined Thelper clones has determined more complex immune mechanisms for the implementation of allergic inflammation. Objective. To characterize the parameters and relationships between the serum cytokine profile and Tlymphocyte subpopulation in peripheral blood of children with bronchial asthma and allergic rhinitis. Materials and methods. 150 children aged between 311 years old with bronchial asthma, and allergic rhinitis and 30 healthy volunteers were examined. Immunological parameters were assessed by flow cytometry, the concentration of serum interleukins and IgE were determined by means of enzymelinked immunosorbent assay. Statistical analysis was performed with Statistica 10 program with a critical level of significance p0.05. Results. High levels of interleukins 4, 8, 13, 17A were determined, IL7F level was not significantly different from that in control group and low level of IFNy was found in the serum of children with allergic diseases. The number of CD3CD8CD45RO, CD3CD8CD45RACD45RO Tlymphocytes, CD3CD4 Thelper cells and Th17 were increased and at the same time CD3CD4CD45RO memory cells were decreased In bronchial asthma and allergic rhinitis children. Number of Th17 cells in healthy children was 9.491.6, in allergic children it was significantly higher 14.50.77 (p0.001). Analyses of serum cytokine count in children with isolated BA and in association with allergic rhinitis revealed multidirectional correlations differing in strength and direction from those in the group of healthy children. Conclusion. In children with isolated bronchial asthma and associated with allergic rhinitis the following parameters were found: CD3CD4 Tcells count was comparable to that in healthy children, the imbalance of Thelper subpopulation: prevalence of Th2 and Th17, activation of IL17A, IL4, IL8, IL13 synthesis and low level of serum IFNy.

scholarly journals EFFICACY AND SAFETY OF NASAL SPRAY PREVALIN IN THE TREATMENT OF ALLERGIC RHINITIS PATIENTS

2012 ◽  
Vol 9 (5) ◽  
pp. 55-59
Author(s):  
A A Tsyvkina ◽  
L V Luss ◽  
S V Tsarev ◽  
N V Shartanova
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Cavity ◽  
Nasal Spray ◽  
Clinical Effect ◽  
Clinical Symptoms ◽  
Efficacy And Safety ◽  
Nasal Breathing ◽  
Results Of Treatment ◽  
Functional Methods ◽  
Positive Clinical Effect

Background. To study of efficacy, tolerability and safety of nasal spray Prevalin in the treatment of allergic rhinitis patients. Methods. 30 patients with allergic rhinitis in the age of18 till 45 years were observed. Prevalin was given as one insufflation into each nasal cavity 3 times a day for 21 days. Results of treatment were assessed by the dynamics of clinical symptoms and the results of functional methods . Results. The positive clinical effect was observed in 22 patients (73,3%), using Prevalin. Clinical effect was characterized by the restoration of nasal breathing, reduce swelling of the nasal mucosa. We did not establish a good result of treatment in 8 patients. Conclusion. The study demonstrated clinical efficacy and safety of spray Prevalin.

scholarly journals Treatment Evaluation with Mometasone Furoate, Alone or in Combination with Desloratadine/ Montelukast in Moderate Severe Allergic Rhinitis

2014 ◽  
Vol 60 (3) ◽  
pp. 106-108 ◽  
Author(s):  
Nona-Aura Florincescu-Gheorghe ◽  
Florica Popescu ◽  
D.O. Alexandru
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Nasal Secretion ◽  
Mometasone Furoate ◽  
Line Treatment ◽  
First Line ◽  
Nasal Symptoms ◽  
A Prospective Study ◽  
First Line Treatment

Abstract Introduction: Allergic rhinitis is one of the most common allergic diseases, characterized by the inflammation of the nasal mucosa. Eosinophils play a predominant pro-inflammatory role in allergic inflammation. This study assesses the effect of mometasone furoate alone or in combination with desloratadine/montelukast in patients with moderate-severe allergic rhinitis. Material and method: This is a prospective study that took place over 8 weeks on 70 patients diagnosed with moderate-severe allergic rhinitis with sensitization to the pollen of Ambrosia elatior. The patients were evaluated on the basis of their symptoms using the total score of nasal symptoms, the score of individual nasal symptoms and the number of eosinophils in the nasal secretion. Results: All 3 groups of patients had an improvement on the total nasal symptoms score. However, the combination of mometasone furoate with desloratadine provided statistically significant benefits on the total score of symptoms and on nasal itching as compared with mometasone furoate alone. Conclusions: The association of mometasone furoate with desloratadine should be considered first-line treatment of moderate-severe allergic rhinitis due to the benefit both on the total symptom score and on of nasal itching.

Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis

1998 ◽  
Vol 118 (5) ◽  
pp. 648-654 ◽  
Author(s):  
E. Minshall ◽  
O. Ghaffar ◽  
L. Cameron ◽  
F. O'Brien ◽  
H. Quinn ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Nasal Mucosa ◽  
Squamous Metaplasia ◽  
Mometasone Furoate ◽  
Biopsy Specimens ◽  
Tissue Changes ◽  
Perennial Rhinitis ◽  
Nasal Biopsy

Allergic rhinitis is associated with specific histopathologic changes in the nasal mucosa including squamous metaplasia and local eosinophilia. Previous studies have shown that mometasone furoate aqueous nasal spray is effective and well tolerated in reducing perennial rhinitis and seasonal allergic rhinitis symptoms. We undertook a multicenter, open-label study to evaluate, by nasal biopsy, the tissue changes associated with mometasone furoate use (200 μg/day) during a 12-month treatment period in patients with perennial rhinitis. Of the 69 patients enrolled in the study, 52 completed all 12 months of treatment. Nasal biopsy specimens obtained from patients at baseline and after treatment were evaluated in a blinded fashion by computerized image analysis, qualitative histologic examination, and immunocytochemistry. Morphologic examination of nasal biopsy specimens showed a decrease in focal metaplasia, no change in epithelial thickness, and no sign of atrophy after treatment with mometasone furoate. Immunocytochemical analyses of nasal biopsy specimens obtained before and after treatment revealed a significant decrease in major basic protein-positive eosinophils and tryptase-positive mast cells in the epithelium and lamina propria after treatment. Mometasone furoate appeared to attenuate the inflammatory process by reducing the extent of inflammatory cell infiltration, particularly of eosinophils. This study demonstrated that long-term administration of mometasone furoate is not associated with adverse tissue changes in the nasal mucosa of patients with perennial rhinitis. (Otolaryngol Head Neck Surg 1998;118:648–54.)

scholarly journals Awareness, use and information sources of folic acid supplementation to prevent neural tube defects in pregnant Japanese women

2017 ◽  
Vol 21 (4) ◽  
pp. 732-739 ◽  
Author(s):  
Shumi Yamamoto ◽  
Yoshinao Wada
Keyword(s):  
Folic Acid ◽  
Pregnant Women ◽  
Folic Acid Supplementation ◽  
Japanese Women ◽  
Reproductive Age ◽  
Current Status ◽  
Public Health Approach ◽  
Childbearing Age ◽  
Acid Supplementation ◽  
Folic Acid Supplements

AbstractObjectiveFolic acid supplementation and folate-rich diets are recommended for women of childbearing age worldwide to prevent congenital anomalies. We aimed to determine the current status of folic acid supplementation among pregnant Japanese women and identify means to increase the intake of these supplements.DesignCross-sectional study.SubjectsA total of 1862 pregnant women who consulted the perinatal centre from September 2014 to December 2015 completed a questionnaire concerning knowledge about folic acid, sources of information and the use of folic acid supplements.SettingOsaka Medical Center and Research Institute for Maternal and Child Health (Japan).ResultsIn our study population, only 20·5 % of pregnant women took folic acid supplements periconceptionally even though 70·4 % knew about the protective effect of folic acid. A multivariate analysis demonstrated that age ≥35 years (OR=2·80; 95 % CI 1·24, 6·29) and knowledge of the benefits of folic acid (OR=2·64; 95 % CI 1·92, 3·62) were associated with periconceptional folic acid use, and multiparity was negatively associated with such use. Compared with those who took folic acid supplements periconceptionally, women who did not take supplements received information through passive and less interactive media.ConclusionsAlthough folic acid awareness was relatively high among pregnant Japanese women, folic acid supplementation before conception was insufficient. To increase the intake of folic acid supplements in countries in which foods are not fortified with folic acid, an effective public health approach promoting behavioural change is necessary for women of reproductive age.

Sign in / Sign up

Export Citation Format

Share Document